JP2023522030A - ネコ科動物抗体バリアント - Google Patents

ネコ科動物抗体バリアント Download PDF

Info

Publication number
JP2023522030A
JP2023522030A JP2022562646A JP2022562646A JP2023522030A JP 2023522030 A JP2023522030 A JP 2023522030A JP 2022562646 A JP2022562646 A JP 2022562646A JP 2022562646 A JP2022562646 A JP 2022562646A JP 2023522030 A JP2023522030 A JP 2023522030A
Authority
JP
Japan
Prior art keywords
igg
constant domain
antibody
feline
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522030A5 (cg-RX-API-DMAC10.html
Inventor
バージェロン,リサ・マリー
カンポス,ヘンリー・ルイス
Original Assignee
ゾエティス・サービシーズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾエティス・サービシーズ・エルエルシー filed Critical ゾエティス・サービシーズ・エルエルシー
Publication of JP2023522030A publication Critical patent/JP2023522030A/ja
Publication of JP2023522030A5 publication Critical patent/JP2023522030A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022562646A 2020-04-17 2021-04-16 ネコ科動物抗体バリアント Pending JP2023522030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011491P 2020-04-17 2020-04-17
US63/011,491 2020-04-17
PCT/US2021/027839 WO2021212084A1 (en) 2020-04-17 2021-04-16 Feline antibody variants

Publications (2)

Publication Number Publication Date
JP2023522030A true JP2023522030A (ja) 2023-05-26
JP2023522030A5 JP2023522030A5 (cg-RX-API-DMAC10.html) 2024-04-22

Family

ID=75870744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562646A Pending JP2023522030A (ja) 2020-04-17 2021-04-16 ネコ科動物抗体バリアント

Country Status (17)

Country Link
US (2) US20240067730A1 (cg-RX-API-DMAC10.html)
EP (1) EP4136109A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023522030A (cg-RX-API-DMAC10.html)
KR (1) KR20230005158A (cg-RX-API-DMAC10.html)
CN (1) CN115667300A (cg-RX-API-DMAC10.html)
AU (1) AU2021257355A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022020631A2 (cg-RX-API-DMAC10.html)
CA (1) CA3176434A1 (cg-RX-API-DMAC10.html)
CL (2) CL2022002856A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014684A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP22080858A (cg-RX-API-DMAC10.html)
IL (1) IL297290A (cg-RX-API-DMAC10.html)
MX (1) MX2022012793A (cg-RX-API-DMAC10.html)
PE (1) PE20230348A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022552743A1 (cg-RX-API-DMAC10.html)
TW (1) TW202204404A (cg-RX-API-DMAC10.html)
WO (1) WO2021212084A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
EP4166574A4 (en) * 2020-06-10 2025-01-15 Bica Therapeutics Inc. FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
IL301414A (en) * 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions
WO2026136223A1 (en) * 2024-12-19 2026-06-25 Zoetis Services Llc Compositions and methods for improving feline antibody functions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086320A1 (en) * 2007-12-26 2009-07-09 Xencor, Inc Fc variants with altered binding to fcrn
US20130022616A1 (en) * 2011-07-21 2013-01-24 Pfizer Inc. Interleukin-31 Monoclonal Antibody
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086320A1 (en) * 2007-12-26 2009-07-09 Xencor, Inc Fc variants with altered binding to fcrn
US20130022616A1 (en) * 2011-07-21 2013-01-24 Pfizer Inc. Interleukin-31 Monoclonal Antibody
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATSUHIKO MAEDA ET AL.: ""Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to r", MABS, vol. 9, no. 5, JPN6025014894, 7 April 2017 (2017-04-07), pages 844 - 853, ISSN: 0005864591 *
CATHERINE J. STRIETZEL ET AL.: ""In Vitro functional characterization of feline IgGs"", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. Vol. 158, No. 3-4, JPN6025014895, April 2014 (2014-04-01), pages 214 - 223, ISSN: 0005864593 *

Also Published As

Publication number Publication date
EP4136109A1 (en) 2023-02-22
CA3176434A1 (en) 2021-10-21
US20240067730A1 (en) 2024-02-29
TW202204404A (zh) 2022-02-01
CL2023003376A1 (es) 2024-04-19
PE20230348A1 (es) 2023-03-02
CO2022014684A2 (es) 2022-11-08
CL2022002856A1 (es) 2023-06-02
BR112022020631A2 (pt) 2022-11-29
US20250026834A1 (en) 2025-01-23
MX2022012793A (es) 2022-11-07
ECSP22080858A (es) 2023-01-31
WO2021212084A1 (en) 2021-10-21
KR20230005158A (ko) 2023-01-09
CN115667300A (zh) 2023-01-31
IL297290A (en) 2022-12-01
PH12022552743A1 (en) 2024-03-25
AU2021257355A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2023522029A (ja) イヌ科動物抗体バリアント
US20250026834A1 (en) Feline antibody variants
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
JP2024503212A (ja) ネコ科動物抗体の定常領域における変異
JP2023543262A (ja) イヌ科動物抗体バリアント
TWI880316B (zh) 貓抗體變異體
RU2840969C1 (ru) Варианты кошачьих антител
JP2025525987A (ja) ウシ亜科動物抗体変異体
HK40121344A (en) Mutations in canine antibody constant regions
JP2025524441A (ja) イヌ科動物抗体変異体
KR20250054824A (ko) 돼지 항체 돌연변이체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260520